CRO Parexel completes registration in India

Mumbai: US-based clinical research organisation (CRO), Parexel, announced the completion of its registration with the Central Drugs Standard Control Organization (CDSCO).

The registration complies with the new G.S.R 581 (E) regulation, which mandates all CROs operating in India to register with CDSCO.

Commenting on the development Sanjay Vyas, President and Managing Director, Parexel India said, “This registration enables us to continue supporting our customers in bringing life-saving treatments to patients safely and efficiently. It reflects our ongoing commitment to meeting regulatory requirements and upholding the highest standards in clinical research.”

Parexel is a 40 year old CRO which operates across multiple global sites and provides the full range of Phase I to IV clinical development services.